Analystreport

CytomX Therapeutics, Inc. (NASDAQ: CTMX) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $2.50 price target on the stock.

CytomX Therapeutics, Inc.  (CTMX) 
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytomx.com